Don't expect immediate impact of US tariff threat: Cipla's CEO

Cipla does not expect any immediate impact from potential tariffs imposed by the US on pharmaceutical imports or from US President Donald Trump's recent order to bring down prescription drug prices, the company's managing director and global chief executive, Umang Vohra, said.

- Jessica Jani

"Our business continues as usual, there's not been any stoppage at any place in the US on account of any confusion with respect to tariffs...and so, we don't see the impact," Vohra said. He added that the company is monitoring ongoing developments, including trade talks between the US and Indian governments. "We don't expect material changes to the business environment for generics," he said.

Trump has not announced tariffs on pharmaceutical products, but he has indicated he will bring in separate tariffs for pharma, aimed at bringing back manufacturing to the US.